

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/074111 A1

(51) International Patent Classification:

G01N 33/543 (2006.01) G01N 33/569 (2006.01)

(21) International Application Number:

PCT/EP2021/077677

(22) International Filing Date:

07 October 2021 (07.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/088,564 07 October 2020 (07.10.2020) US
21315057.6 30 March 2021 (30.03.2021) EP

(71) Applicants: **SANOPI PASTEUR** [FR/FR]; 14 Espace
Henry Vallée, 69007 Lyon (FR). **CTK BIOTECH, INC.**
[US/US]; 13855 Stowe Dr., Poway, California 92064 (US).

(72) Inventors: **ATAMAN-ONAL, Yasemin**; c/o Sanofi,
Patent Department, 54 Rue La Boétie, 75008 Paris (FR).
BONAPARTE, Matthew; c/o Sanofi Pasteur Inc., IP
Dept., 38 Sydney Street, Cambridge, Massachusetts 02140
(US). **CHEN, Catherine**; c/o CTK Biotech, Inc., 13855
Stowe Dr., Poway, California 92064 (US). **LIBERAL,**
Vasco; c/o CTK Biotech, Inc., 13855 Stowe Dr., Poway,
California 92064 (US). **PAN, Qilin**; c/o CTK Biotech,
Inc., 13855 Stowe Dr., Poway, California 92064 (US).
SAVARINO, Stephen; c/o Sanofi Pasteur Inc., IP Dept.,
38 Sydney Street, Cambridge, Massachusetts 02140 (US).
YIN, Wushan; c/o CTK Biotech, Inc., 13855 Stowe Dr.,
Poway, California 92064 (US). **ZHENG, Lingyi**; c/o Sanofi
Pasteur Inc., IP Dept., 38 Sydney Street, Cambridge, Mass-
achusetts 02140 (US).

(74) Agent: **ABEL & IMRAY**; Westpoint Building, James
Street West, Bath, Bath and North East Somerset BA1 2DA
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: IMPROVED DIAGNOSTIC TESTS

(57) Abstract: The present invention provides an immunodiagnostic test device for the detection of anti-dengue virus antibodies comprising a first dengue antigen and a second dengue antigen, wherein said first dengue antigen comprises a polypeptide having at least 90% sequence identity to SEQ ID NO. 1 and said second dengue antigen comprises a polypeptide having the sequence of SEQ ID NO. 2 or a polypeptide having a sequence which has at least 1 and no more than 4 amino acid substitutions with respect to the sequence of SEQ ID NO. 2.

WO 2022/074111 A1